Supernus Pharmaceuticals (NasdaqGM:SUPN) FY Conference Transcript

Supernus Pharmaceuticals FY Conference Summary Company Overview - Company: Supernus Pharmaceuticals (NasdaqGM:SUPN) - Date of Conference: March 02, 2026 - Key Speakers: Jack Khattar (CEO), Timothy C. Dec (CFO) Key Points Industry and Company Position - Supernus is positioned differently today with a diverse portfolio of products, moving beyond reliance on a single product [2] - The company has four growth products and is experiencing accelerated growth with an exciting pipeline [2][3] Product Performance - ONAPGO: Recently reinitiated patient treatment after resolving supply constraints. The product has strong demand, evidenced by 500 patient forms submitted during supply issues [4][5][6] - ZURZUVAE: Launched with a focus on educating women about postpartum depression, aiming to increase awareness and usage [51][52] - Qelbree: Continues to perform well, with a stable mix of adult and pediatric prescriptions. The product is underutilized in the non-stimulant segment, presenting significant growth potential [42][43][44] Financial Guidance - ONAPGO revenue guidance is set between $45 million and $70 million, influenced by supply, demand, and fulfillment rates [24][26] - Peak sales for ONAPGO may exceed initial estimates of $200 million to $300 million due to overwhelming demand [38][40] Patient Demand and Market Dynamics - Demand for ONAPGO is strong, with patients willing to wait through supply disruptions rather than switch to competitors [10][12] - The company anticipates a conversion rate of 15%-25% from patient forms to actual patients, which is typical in the industry [22] Pipeline and Future Developments - The company is optimistic about its pipeline, with promising assets in Phase 2b studies expected to yield data in 2027 [59] - Supernus is actively pursuing business development opportunities, focusing on revenue-generating assets and later-stage products [58] Manufacturing and Supply Chain - A second supplier is expected to come online in 2027, which will help mitigate supply issues [29][32] - The company is working to streamline the patient initiation process to reduce friction points in fulfillment [23] Market Education and Awareness - Significant investment in educating healthcare providers and patients about ZURZUVAE and its benefits over traditional SSRIs [51][52][55] - The company aims to establish ZURZUVAE as the standard of care for postpartum depression [55] Conclusion - Supernus Pharmaceuticals is navigating a transformative phase with a robust product pipeline and strategic focus on market education and patient demand. The company is well-positioned for growth in the coming years, particularly with ONAPGO and ZURZUVAE.